Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

446 results
Display

Cost-effectiveness of chronic hepatitis C screening and treatment

Lee HW, Lee H, Kim BK, Chang Y, Jang JY, Kim DY

Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective

Kim HL, Kim KA, Choi GH, Jang ES, Ki M, Choi HY, Jeong SH

Background/Aims: This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives. Methods: A published...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials

Heo J, Kim YJ, Lee JW, Kim JH, Lim YS, Han KH, Jeong SH, Cho M, Yoon KT, Bae SH, Crown ED, Fredrick LM, Alami NN, Asatryan A, Kim DH, Paik SW, Lee YJ

Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea

Lim DH, Jeong JY, Nam S, Choi J, Kwon HC, Yoon YB, Kim Y, Chin B

Background: Because of the very low incidence of human immunodeficiency virus (HIV) coinfection in Korea, data on hepatitis C virus (HCV)/HIV coinfection are limited. This study aimed to investigate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination

Brunner N, Bruggmann P

Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J

Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study

Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW

Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY

Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution

Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M

Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2

Han SY, Woo HY, Heo J, Park SG, Pyeon SI, Park YJ, Kim DU, Kim GH, Kim HH, Song GA, Cho M

Background/Aims: Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of Results of Liver-related Health Care Checkup in Mongolian Immigrants: A Comparison with Results from Koreans

Kim DH, Lee JK, Kim H, Oh Ac, Hong YJ, Park SC, Kong CB

Background: The incidence and mortality rate of liver cancer in Mongolians are known to be the highest in the world, and liver cancer in Mongolians is mainly caused by chronic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current and future strategies for the treatment of chronic hepatitis C

Alshuwaykh O, Kwo PY

Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Influence of Test Parameters on the Performance of Rapid Anti-Hepatitis C Virus Immunochromatographic Assay

Choi EJ, Kim JH, Han MS

Anti-hepatitis C virus (HCV) immunochromatographic assay (ICA) is commonly used as an early screening test for HCV infection. This study evaluated the influence of test parameters (technician, assay type, kit...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area

Shin J, Yu JH, Jin YJ, Lee JW

Background/objective: Hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) is rarely observed in patients without liver cirrhosis (LC). We evaluated the incidence and clinical feature of HCV-associated HCC patients with or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Epidemiological and Clinical History of Viral Hepatitis in Korea

Yoon JH, Cho SH, Kim DY, Yu SJ, Han KH

Viral hepatitis is the most important cause of acute and chronic liver disease in Korea. Particularly, hepatitis B virus (HBV) is the leading cause of liver-related mortality. Because of the nationwide...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study

Chung JW, Choi HY, Ki M, Jang ES, Jeong SH

Background/Aims: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study

Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH

Background/Aim: This study aimed to establish the real-world effectiveness and safety of grazoprevir/elbasvir (EBR/GZR) therapy in South Korea. Methods: A total of 242 patients with chronic hepatitis C virus (HCV) genotype...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma

Kwan BS, Kim JH, Park SJ, Choe WH, Kwon SY, Yoo BC

Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Healthcare-Associated Outbreak of HCV Genotype 2a at a Clinic in Seoul

Choi S, Lee H, Lee H, Chung YS

Objectives: An epidemiological investigation was conducted into a hepatitis C virus (HCV) outbreak at an outpatients clinic in Seoul (2011-2012). The aim of the study was to analyze the scale...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals

Lee DH, Ryu SH, Myung Hj, Shin YJ, Lee SH, Park TY, Moon JS

The pegylated interferon plus ribavirin combination therapy has been used as the primary treatment for chronic hepatitis C (CHC) but fails to produce a sustained viral response (SVR) in many...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr